Epidemiology and treatment utilization for Canadian patients with migraine: a literature review
The objective of this narrative review was to identify real-world evidence regarding the burden of migraine in Canada. We conducted a literature search in MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for studies published between August 2010 and August 2020. Of the 3269 publicati...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-09-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605221126380 |
| _version_ | 1811206907236450304 |
|---|---|
| author | Erin B Graves Brittany R Gerber Patrick S Berrigan Eileen Shaw Tara M Cowling Marie-Pier Ladouceur Joanna K Bougie |
| author_facet | Erin B Graves Brittany R Gerber Patrick S Berrigan Eileen Shaw Tara M Cowling Marie-Pier Ladouceur Joanna K Bougie |
| author_sort | Erin B Graves |
| collection | DOAJ |
| description | The objective of this narrative review was to identify real-world evidence regarding the burden of migraine in Canada. We conducted a literature search in MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for studies published between August 2010 and August 2020. Of the 3269 publications identified, 29 studies were included. Prevalence estimates varied widely across Canada, and mental health comorbidities were common. Individuals with migraine have a lower quality of life, detrimental impact on workforce productivity, and higher rates of health care resource utilization (HCRU), with HCRU and costs highest among those with chronic migraine. We found inconsistencies in care, including underutilization of medications such as triptans, and varied utilization of over-the-counter and prescription medications. Increased medication use was identified among those with chronic migraine, and only a small number of patients used migraine preventive medications. The burden of migraine in Canada is substantial. Reduced quality of life and workforce productivity, increased HCRU and costs, and underutilization of triptans and migraine preventive medications highlight an important need for more effective management of individuals with migraine. |
| first_indexed | 2024-04-12T03:55:58Z |
| format | Article |
| id | doaj.art-4123a4e9983f45ca893cc0a51f8044cc |
| institution | Directory Open Access Journal |
| issn | 1473-2300 |
| language | English |
| last_indexed | 2024-04-12T03:55:58Z |
| publishDate | 2022-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj.art-4123a4e9983f45ca893cc0a51f8044cc2022-12-22T03:48:50ZengSAGE PublishingJournal of International Medical Research1473-23002022-09-015010.1177/03000605221126380Epidemiology and treatment utilization for Canadian patients with migraine: a literature reviewErin B GravesBrittany R GerberPatrick S BerriganEileen ShawTara M CowlingMarie-Pier LadouceurJoanna K BougieThe objective of this narrative review was to identify real-world evidence regarding the burden of migraine in Canada. We conducted a literature search in MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for studies published between August 2010 and August 2020. Of the 3269 publications identified, 29 studies were included. Prevalence estimates varied widely across Canada, and mental health comorbidities were common. Individuals with migraine have a lower quality of life, detrimental impact on workforce productivity, and higher rates of health care resource utilization (HCRU), with HCRU and costs highest among those with chronic migraine. We found inconsistencies in care, including underutilization of medications such as triptans, and varied utilization of over-the-counter and prescription medications. Increased medication use was identified among those with chronic migraine, and only a small number of patients used migraine preventive medications. The burden of migraine in Canada is substantial. Reduced quality of life and workforce productivity, increased HCRU and costs, and underutilization of triptans and migraine preventive medications highlight an important need for more effective management of individuals with migraine.https://doi.org/10.1177/03000605221126380 |
| spellingShingle | Erin B Graves Brittany R Gerber Patrick S Berrigan Eileen Shaw Tara M Cowling Marie-Pier Ladouceur Joanna K Bougie Epidemiology and treatment utilization for Canadian patients with migraine: a literature review Journal of International Medical Research |
| title | Epidemiology and treatment utilization for Canadian patients with migraine: a literature review |
| title_full | Epidemiology and treatment utilization for Canadian patients with migraine: a literature review |
| title_fullStr | Epidemiology and treatment utilization for Canadian patients with migraine: a literature review |
| title_full_unstemmed | Epidemiology and treatment utilization for Canadian patients with migraine: a literature review |
| title_short | Epidemiology and treatment utilization for Canadian patients with migraine: a literature review |
| title_sort | epidemiology and treatment utilization for canadian patients with migraine a literature review |
| url | https://doi.org/10.1177/03000605221126380 |
| work_keys_str_mv | AT erinbgraves epidemiologyandtreatmentutilizationforcanadianpatientswithmigrainealiteraturereview AT brittanyrgerber epidemiologyandtreatmentutilizationforcanadianpatientswithmigrainealiteraturereview AT patricksberrigan epidemiologyandtreatmentutilizationforcanadianpatientswithmigrainealiteraturereview AT eileenshaw epidemiologyandtreatmentutilizationforcanadianpatientswithmigrainealiteraturereview AT taramcowling epidemiologyandtreatmentutilizationforcanadianpatientswithmigrainealiteraturereview AT mariepierladouceur epidemiologyandtreatmentutilizationforcanadianpatientswithmigrainealiteraturereview AT joannakbougie epidemiologyandtreatmentutilizationforcanadianpatientswithmigrainealiteraturereview |